表皮生长因子酪氨酸激酶抑制剂一线治疗突变阳性晚期非小细胞肺癌的临床疗效预测因素分析

BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated some dramatic efficacy in advanced non-small-cell lung cancer (NSCLC) patients with activating EGFR mutation. However, progression-free survivals (PFS) among those patients who were tr...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2019
Materias:
临床研究
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397942/
https://www.ncbi.nlm.nih.gov/pubmed/30827326
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.02.04

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397942/
https://www.ncbi.nlm.nih.gov/pubmed/30827326
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.02.04

Ejemplares similares